The Conversation (0)
InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet Stent Jacket and Related Drug Eluting Technology
Sep. 17, 2018 09:03AM PST
Medical Device Investing
InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced that the United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary MicroNet™ stent jacket combined with a stent scaffold and related drug eluting …
InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced that the United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary MicroNet™ stent jacket combined with a stent scaffold and related drug eluting technologies.
As quoted in the press release:
“We are pleased that the USPTO has recognized this unique technology that we believe can revolutionize the field of vascular stenting in general, but more importantly, prevent stroke in patients with carotid artery disease,” said James Barry, PhD, Chief Executive Officer of InspireMD. “Conventional stenting in patients being treated for carotid artery disease allows for the protrusion of plaque through the stent struts and into the blood vessel in up to 65% of cases, significantly increasing the risk of stroke and other complications post-procedure. However, our novel MicroNet stent jacket technology acts as a safety net that prevents debris from passing through the mesh, resulting in significantly lower complication rates versus conventional stenting. These patents also strengthen and broaden our overall product and technology portfolio with the inclusion of claims covering drug eluting technologies. Combining MicroNet with drug eluting capabilities would be a key differentiating feature of our coronary stent product, MGuard Prime EPS, and any other drug eluting stent product, creating what we believe are broad potential applications in the coronary drug eluting stent market.”
Dr. Barry continued, “We look forward to further executing on our growth strategy, which includes the expansion of our commercial footprint, both in countries where we have established distribution as well as new geographies. We are also working to submit a U.S. investigational device exception (IDE) for CGuard EPS to FDA expected in mid-2019 as we begin the process of accessing the U.S. Market.”
